InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
7
T+90 hit rate
20%
T+90 mean return
-23.4%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Rangwala Reshma, Vice-Présidente Exécutive et Directrice Médicale. Director active across 1 company, notably Karyopharm Therapeutics Inc.. Cumulatively, 15 filings have been recorded. Split: 0 buy · 7 sells. Total volume traded: €93k. History available since 29 April 2022. The latest transaction was disclosed on 13 May 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Rangwala Reshma
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
947 shares0Common StockSEC:0001193125-26-226685:0
449 shares@ US$8.940.0018% mcap6.6% of flowCommon StockSEC:0001825322-26-000006:0
5,066 shares@ US$9.4095Common StockSEC:0001825322-26-000003:0
32,415 shares0Common StockSEC:0001193125-26-035682:0
945 shares0Common StockSEC:0001193125-25-205044:0
419 shares@ US$6.174.7% of flowCommon StockSEC:0000950170-25-058137:0
3,587 shares@ US$6.2944.3% of flowCommon StockSEC:0000950170-25-034732:0
5,416 shares0Common StockSEC:0000950170-25-032315:0
6,789 shares@ US$1.1715.3% of flowCommon StockSEC:0000950170-24-046871:0
15,667 shares@ US$1.1734.8% of flowCommonSEC:0000950170-24-025193:0
198,959 shares0Common StockSEC:0000950170-24-023297:0
14,167 shares0Common StockSEC:0000950170-24-007614:0
115 shares@ US$4.02670.9% of flowCommon StockSEC:0001209191-23-025464:0
100,000 shares0Common StockSEC:0001209191-23-014873:0
65,000 shares0Common StockSEC:0001209191-22-026425:0
15 of 15 declarations
About Rangwala Reshma
Reshma Rangwala is the EVP & Chief Medical Officer at Karyopharm Therapeutics Inc. She oversees the company's medical and scientific initiatives, ensuring that research and development meet the highest standards. Her expertise is crucial for the success of the company's therapeutic programs.
